MPAM
RCUS icon

Monarch Partners Asset Management’s Arcus Biosciences RCUS Stock Holding History

Monarch Partners Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.22M Buy
58,847
+417
+0.7% +$11.5K 0.36% 122
2022
Q3 		$1.53M Buy
+58,430
New +$1.55M 0.46% 109

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Monarch Partners Asset Management's RCUS Position: Q4 2022 in Review

Monarch Partners Asset Management increased its Arcus Biosciences (RCUS) stake by 0.71% in Q4 2022, buying an estimated $11.5K and bringing the position to 58,847 shares worth $1.22M. The position accounts for 0.36% of the portfolio, ranked #122.

Monarch Partners Asset Management first reported a position in RCUS in Q3 2022 and has held it in 2 quarters since. The position peaked at $1.53M in Q3 2022. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • Monarch Partners Asset Management held 58,847 shares of Arcus Biosciences worth $1.22M as of Q4 2022.
  • Monarch Partners Asset Management bought 417 Arcus Biosciences shares in Q4 2022, an estimated $11.5K.
  • Arcus Biosciences made up 0.36% of Monarch Partners Asset Management's portfolio in Q4 2022, its #122 holding.
  • Monarch Partners Asset Management first reported a position in Arcus Biosciences in Q3 2022 and has held it in 2 quarters since.
  • Monarch Partners Asset Management's Arcus Biosciences position peaked at $1.53M in Q3 2022.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.